Table 2:

Summary of Results

Result	Total	ANT-DBS	CM-DBS	RNS	CSS	VNS	P value
Median Seizure Frequency Reduction % (IQR)	61 (IQR 5–90)§	52 (IQR 15–86)	63 (IQR 0–85)	50 (IQR 31–89)	85 (IQR 57–100)†	50 (IQR 0–90)	0.07
Responder Rate % (n)	60 (95)	55 (21)	58 (11)	56 (17)	81 (25)	53 (21)	0.14
Seizure freedom for at least 3 mo at last FU % (n)	14 (22)	11 (4)		17 (5)	29 (9)	10 (4)	0.04
Median Convulsive Seizure Frequency Reduction % (IQR)	70 (0–97)§	95 (25–100)	63 (0–95)‡	63 (40–100)	75 (30–100)	54 (0–94)‡	0.57
Seizure Severity Improvement (Range)*	2 (−4 to 9)§	2 (−3 to 7)	2 (−3 to 7)	2 (−4 to 7)	3 (−3 to 8)	3 (−3 to 9)	0.51
Life Satisfaction Improvement (IQR)**	2 (−7 to 9) §	1 (−7 to 6)	2 (−6 to 6)	2 (−6 to 6)	3 (−5 to 8)	2 (−6 to 9)	0.58
Quality of Sleep Improvement (IQR)**	1 (−6 to 9)§	1 (−4 to 5) ‡	0 (−1 to 9)	1 (−5 to 8) ‡	2 (−6 to 8)	1 (−3 to 7) ‡	0.14
Follow-up Time mo (IQR)	26 (13–52)	23 (11–28)	27 (17– 81)	19 (10–30)‡	32 (9–59)	50 (26–73)	<0.001

ANT-DBS, anterior thalamic nuclei deep brain stimulation; CM-DBS, centromedian thalamic nuclei deep brain stimulation; CSS, chronic subthreshold stimulation; IQR, interquartile range; mo, months; RNS, responsive neurostimulation; VNS, vagus nerve stimulation.

^*Pre-implantation value minus post-implantation value, higher numbers indicate a decrease in seizure severity, expressed as mean value with range.

^**Post-implantation value minus pre-implantation value, higher numbers indicate an increase in life satisfaction and quality of sleep, expressed as mean values with ranges.

^§p<0.001 Wilcoxon signed rank test compared to a median of 0

^†Significantly different in unadjusted pairwise comparisons (Mann-Whitney U) with ANT-DBS (p=0.01), CM-DBS (p=0.04), RNS (0.04) and VNS (p=0.02)

^‡Not statistically significant on individual group test between pre and post implantation values (Wilcoxon signed-rank test)